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Abstract
CASPASE-12 (CASP12) has an anti-inflammatory function during infection. To determine and if CASP12 could
protect against inflammatory disease, we investigated the distribution of CASP12 alleles in African-Americans (AA)
with rheumatoid arthritis (RA). CASP12 homozygous patients had lower baseline joint narrowing and total disease
scores. However, there was no significant difference for distribution of CASP12 genotypes between AA controls and
patients with RA, or any other clinical criteria for this disease. CASP12 homozygosity appears to be, at best a subtle
protective factor for some aspects of RA in AA patients. This raises an intriguing issue as to how this protein would
not have a more significant role in an inflammatory disease process.
Introduction
Most humans lack a functional CASP12 gene. A pseudogene
(CASP12p1) resulting from a premature termination mutation [1] is
found in all Caucasians and East Asians examined, and in 80% of
people of African lineage [2,3]. In approximately 20% of persons of
recent African descent, the pseudogene is rescued by a single
nucleotide polymorphism (#rs497116; A→G) that converts the
premature stop codon into a functional one encoding Arg [2,3].
This functional allele is a risk factor for sepsis in persons of African
descent in response to pro-inflammatory mediators such as bacterial
lipopolysaccharide. This is due to CASP12’s ability to down-regulate
production of inflammatory cytokines such as interleukin (IL)-1β or
tumor necrosis factor (TNF) and by interfering with the activation of
the transcription factor NFκb [4,5]. In individuals of African descent
with severe sepsis, the mortality rate was 54% in individuals with the
CASP12 allele, compared with 17% in individuals with only the
CASP12p1 allele. Knockout mice lacking CASP12 are also less
susceptible to sepsis and death than wild-type mice [6]. These anti-
inflammatory activities are proposed to result from CASP12 biding to
inflammasome components such as CASP1 and CASP5 [6] and/or to
adaptor proteins downstream of pattern recognition molecules, such as
NOD2 [7] or RIG-I [8].
The intact allele of CASP12 is still found in approximately 20% of
African-Americans, with higher allele frequencies in some populations
in sub-Saharan Africans, and in some populations of Central and
South Asians [2,3,9]. This implies that despite its selective
disadvantage, it may play a protective in inflammatory processes
exploited by specific pathogens [10].
A corollary to the observation that CASP12 is a risk factor for sepsis
would be that CASP12 is protective against some inflammatory
autoimmune diseases. If CASP12 causes a derangement in IL-1β or
TNF production, individuals carrying the CASP12 allele, but not
CASP12p1, should be less likely to develop inflammatory disease. To
test this hypothesis, we sought to determine if CASP12 genotype would
have an effect upon the pathologic manifestations of rheumatoid
arthritis (RA). We genotyped CASP12 in patients and controls from
the Consortium for Longitudinal Evaluation of African-Americans
with Early Rheumatoid Arthritis (CLEAR) and the Veterans
Administration Rheumatoid Arthritis (VARA) Registry of African-
Americans with RA [11,12].
CASP12 genotype was assessed for several diagnostic criteria for
RA according to the 1987 American College of Rheumatology (ACR)
RA classification criteria [13]. These include scored radiographic
changes (joint erosion, joint space narrowing and their combined
scores), presence of rheumatoid nodules or serum rheumatoid factor
(RF), and the number of tender or swollen joints (out of 28) at
baseline. In addition, we compared genotype to serologic criteria from
the 2010 ACR/EULAR classification [14] for elevated C-reactive
protein levels, elevated erythrocyte sedimentation rate, and presence of
anti-citrullinated peptide antibodies (anti-CCP).
Our data found that frequencies of CASP12 alleles in both patients
and controls were similar to normal controls reported by others [4,15].
There were no significant differences in the genotype and allele
frequency between controls and RA patients, nor did genotype affect
seropositivity of RF or anti-CCP. As expected, while nearly 20% of the
controls were positive for RF, and only 3% were so for anti-CCP, and
there was no connection to CASP12 genotype.
While possession of intact CASP12 had no overall effect upon the
development of RA in AA, there was a subtle protective effect against
the erosive pathologies of RA, as defined by radiographic changes of
baseline joint erosion and joint space narrowing scores. Baseline joint
narrowing and total disease scores were greater in those patients who
were homozygous for the CASP12p1 pseudogene than those who were
CASP12 homozygous. Joint erosion scores also appeared to be greater
in CASP12p1 homozygotes, although not reaching statistical
significance. No significant differences were found for any other
clinical parameters.
Two questions arise from these findings. The first is how do the
joint pathologies in RA arise? The second is what role does CASP12
play in autoimmune pathogenesis, if any?
The pathology of RA is mediated by chronic joint inflammation and
synovial hyperplasia that ultimately lead to cartilage degradation and
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bone destruction [16,17]. The major cellular effectors of these events
CD4+ Th17 cells, which drive the process by the secretion of
inflammatory cytokines either directly or indirectly from
inflammatory cells [18-20]. Given the role of IL-1β and TNF in the
pathogenesis of RA [18,21], the findings hint at pathways involved in
the severity of joint damage, and open the possibility of identifying
novel biomarkers for RA severity and disease progression, which, to
date, are relatively few [22].
It is unknown how CASP12 exerts the protective effects described
above. If CASP12 is indeed down regulatory, it may fail to reduce
serum concentrations of IL-1β or other pathogenic cytokines below
disease-inducing levels, but does so at the tissue or cellular level. This
notion is supported by the observation that there is less macrophage
infiltration into adipose tissues of obese African-American children
who are CASP12-positive [23].
The key question emerging is CASP12 actually anti-inflammatory?
Our own findings bring to mind “the dog that didn’t bark”. In the
classic Sir Arthur Conan Doyle tale The Adventure of the Silver Blaze,
Sherlock Holmes noted that the guard dog was supposed to bark at
prowlers in the night, yet didn’t do so prior to the occurrence of a
crime [24]. And so human CASP12 is posited to downregulate
inflammation mediated by cytokines, to such an extent that this
activity renders a subject more susceptible to sepsis. This would explain
the near extirpation of the functional allele from the vast majority of
the human population [2,3].
Saleh and colleagues extended their finding on CASP12 and IL1-β
to other inflammatory cytokines with the observation that in obese
African-American children who are CASP12-positive have lower
serum IL6 and C-reactive protein levels [23]. Unfortunately, these
workers did not report on any findings concerning IL-1β or TNF;
perhaps IL-1β is not triggered at a systemic level following
metabolism-based inflammation, but IL-1β is activated by non-
CASP1-mediated mechanisms in different disease states [21] or IL-1β
production is not affected by CASP12. We lean toward the latter
interpretation.
CASP12 genotype does not influence susceptibility or adverse
events in African-Americans or black South Africans with community-
acquired pneumonia [15]. In addition, susceptibility to Candida sepsis
in Africans is not affected by CASP12 genotype, nor does it have any
effect on serum inflammatory cytokine concentrations in the
pathology of candidiasis [23] or in in vitro responses to Yersinia pestis
[25]. While malaria would be an obvious candidate for a positive
selective effect upon maintenance of CASP12, there is no association
between CASP12 genotype and either the presentation of severe
malaria or outcomes in individual clinical parameters in malaria
patients [26].
CASP12’s effects upon TNF production, which is elevated in all
lupus patients, especially African-Americans [27], is also contradictory
[5,25,28]. Further, while hepatitis C virus is an IL-1β inducer [29]
CASP12 genotype has no effect in the clearance of this pathogen [30].
Confounding the metabolic findings described above by Skeldon and
co-workers, no protective effects are found in African-American adults
with CASP12 when metabolic parameters or C-reactive protein levels
were assessed [23].
When we examined another inflammatory autoimmune disease in
African-Americans, systemic lupus erythematosus (SLE), we found
that CASP12 genotype was neither a risk factor nor protective. CASP12
polymorphisms did not affect any of the 11 ACR classification criteria,
nor did our data demonstrate that CASP12 genotype had a significant
effect upon serum IL-1β levels in an initial screen of sera from 14
patients. At best, we found a weak protective effect against the
development of anti-double-stranded DNA antibodies, but no other
autoantibodies (T. Fuchs, J.A. Kelly, E. Simon, K.L. Sivils and E.
Hermel; in press, Immunology Lett.). It is also worth noting that in
transgenic mice carrying human CASP12, the gene is downregulated
in female mice, due to an endogenous estrogen response element [5].
This might explain why 90% of AA SLE patients are female [31] but is
confounded by the observation that African-American male lupus
patients have a more severe phenotype and worse outcomes [32,33].
While different findings for CASP12 effects (or lack thereof)
described here may be due to sample size, populations tested,
underlying disease states assessed, or the assay systems used, using
CASP12 genotype to predict protection in rheumatic diseases, or even
in infectious disease outcomes, appears to be problematic.
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